Tisagenlecleucel Versus Blinatumomab or Inotuzumab for Adult Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Randomized Open Label, Multicenter, Phase III Trial
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Tisagenlecleucel (Primary) ; Blinatumomab; Inotuzumab ozogamicin
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms OBERON
- Sponsors Novartis Pharmaceuticals
- 04 Feb 2019 Planned End Date changed from 22 Dec 2022 to 22 Feb 2023.
- 04 Feb 2019 Planned primary completion date changed from 26 Feb 2021 to 22 Feb 2023.
- 04 Feb 2019 Planned initiation date changed from 17 Jan 2019 to 20 Mar 2019.